Beth Anne Lang

Beth Anne Lang has a robust background in regulatory affairs spanning over two decades, currently serving as Senior Vice President of Regulatory Affairs at Liquidia Corporation since May 2025. Previous roles include Senior Vice President positions at Priovant Therapeutics, Akari Therapeutics, and Enzyvant, alongside significant leadership at Altavant Sciences and Horizon. Notable tenure at Takeda involved various leadership roles in Global Regulatory Affairs focusing on marketed products and developing regulatory strategies for novel therapeutics, particularly in the cardiovascular and metabolic areas. Early career experience includes regulatory strategy and quality roles at TAP Pharmaceuticals and Abbott Laboratories. Beth Anne Lang holds an MBA from Marquette University and a BS in Food Science and Microbiology from the University of Illinois Urbana-Champaign, with ongoing doctoral studies in Public Health at Walden University.